National and Kapodistrian University of Athens
Σύνθεση συμπλόκων Pt(II) και Ru(II) με υποκαταστάτες βιολογικού ενδιαφέροντος
Abstract
dc:descriptionThe synthesis, characterization and biological properties of novel platinum(II) and ruthenium(II) complexes with dicarboxylate ligands as potential antitumor and antimetastatic agents, are described in this thesis. The platinum complexes were synthesized via solid phase approach, which is a new and very promising technique. According to this method, two amino acids are consecutively condensed to a resin, which is followed by the attachment of the platinum-chelating moiety. Before the cleavage of the resin, the platination takes place. Alternatively, the platination of the linker takes place in advance, and then this conjugate is condensed to the solid fixed dipeptide. The final step in both routes is the cleavage of the solid support (resin) giving the peptide-platinum compound. Two novel compounds were isolated, B614 and B617, which both contain the glycine-glycine dipeptide. In compound Β614, platinum is bound to the peptide by the two carboxylic groups of the linker while two ammonia molecules occupy the other two sites of the platinum coordination sphere. Contrarily, in compound Β617, platinum is bound to a diamine moiety while the chelating ligand 1,1-cyclobutane dicarboxylate (cbdc) occupies the other two sites of the platinum coordination sphere. The characterization of the starting materials, the intermediates and the final compounds has been carried out by means of NMR spectroscopy (1H, 195Pt, COSY) and mass spectroscopy (LCMS). The ruthenium(II) complexes were synthesized following the traditional methods (synthesis in solution) since very little is know about the reactivity of ruthenium towards dicarboxylates. The dicarboxylates which were used were: oxalate (ox), malonate (mal), 1,1-cyclobutane dicarboxylate (cbdc), and succinate (suc). The products obtained were 1) mononuclear (the ligand acts as chelate): K[fac- RuCl(dmso-S)3(η2-ox-O,O/)] (B71), [fac-RuCl(dmso-S)3(η2-ox-O,O/)] (B73), K[fac-RuCl(dmso-S)3(η2-mal- O,O/)]·2H2O (B81), fac-Ru(dmso-S)3(dmso-O)(η2-mal-O,O/) (Β82), K[fac-RuCl(dmso-S)3(η2-cbdc-O,O/)]·2H2O (B91), 2) dinuclear (the ligand acts as bridge): {fac-Ru(dmso-S)3(H2O)(μ-mal-O,O/)}2 (Β83), {fac-Ru(dmso- S)3(H2O)(μ-cbdc-O,O/)}2 (Β92), {fac-Ru(dmso-S)3(NH3)(μ-cbdc-O,O/)}2 (Β93), {fac-Ru(dmso-S)3(H2O)(μ-suc- O,O/)}2 (Β101), 3) dinuclear (the ligand acts as bis-bidentate): [{fac-Ru(dmso-S)3(Cl)}2(η4,μ-ox)] (B72), [{fac- Ru(dmso-S)3(dmso-O)}2(η4,μ-ox)](CF3SO3)2 (B74) and 4) tetranuclear (the ligand acts both as chelate and bridge): {fac-Ru(dmso-S)3(η3,μ-ox)}4 (Β75). All complexes were fully characterized by elemental analysis and variety of spectroscopic methods such as 1D and 2D NMR (1H, 13C, COSY, HMQC), IR, UV-Vis. The molecular structures of the complexes Β72, Β74, Β75, Β81, Β82, Β83, Β92, Β93 και Β101 were determined by X-Ray crystallography. The chemical behavior in aqueous solution of all Ru-dmso-dicarboxylate complexes was extensively studied, and some in vitro biological experiments were performed in order to evaluate their potential antitumor activity.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2005
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bratsos, Ioannis
- Μπράτσος, Ιωάννης
Subjects
dc:subject × 20- Λευκόχρυσος
- Ρουθήνιο
- Αντικαρκινικά
- Δικαρβοξυλικοί υποκαταστάτες
- Διμεθυλοσουλφοξείδιο
- 1,1-κυκλοβουτανοδιϊκό ιόν
- Οξαλικά
- Μηλονικό ιόν
- Platinum
- Ruthenium
- Antitumor
- Dicarboxylates
- Dimethylsulfoxide
- 1,1-cyclobutane dicarboxylate
- Oxalate
- Malonate
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21234